Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$114M |
| 2 |
BKI
Black Knight, Inc. Common Stock
BKI
|
+$31.3M |
| 3 |
PARA
Paramount Global Class B
PARA
|
+$26.4M |
| 4 |
Tyler Technologies
TYL
|
+$25M |
| 5 |
Brown & Brown
BRO
|
+$18.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$249M |
| 2 |
CELG
Celgene Corp
CELG
|
+$231M |
| 3 |
Microsoft
MSFT
|
+$171M |
| 4 |
Alibaba
BABA
|
+$140M |
| 5 |
Amazon
AMZN
|
+$99.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.49% |
| 2 | Healthcare | 14.66% |
| 3 | Consumer Discretionary | 11.66% |
| 4 | Communication Services | 10.19% |
| 5 | Industrials | 9.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LTHM
1626
DELISTED
Livent Corporation
LTHM
| $2.39M | ﹤0.01% |
279,435
+5,000
| +2% | +$38.2K |
|
|
APHA
1627
DELISTED
Aphria Inc. Common Shares
APHA
| $2.39M | ﹤0.01% |
458,100
+6,800
| +2% | +$33.4K |
|
1628
Pathward Financial
CASH
$1.79B
| $2.39M | ﹤0.01% |
65,400
-1,200
| -2% | -$40.8K |
|
|
CORE
1629
DELISTED
Core Mark Holding Co., Inc.
CORE
| $2.38M | ﹤0.01% |
87,700
+1,300
| +2% | +$36K |
|
1630
Supernus Pharmaceuticals
SUPN
$2.74B
| $2.38M | ﹤0.01% |
100,400
+2,000
| +2% | +$48.6K |
|
|
VBTX
1631
DELISTED
Veritex Holdings
VBTX
| $2.37M | ﹤0.01% |
81,417
| – | – |
|
1632
Corcept Therapeutics
CORT
$11.9B
| $2.37M | ﹤0.01% |
195,900
+2,000
| +1% | +$27.8K |
|
1633
Tompkins Financial
TMP
$1.45B
| $2.37M | ﹤0.01% |
25,900
| – | – |
|
1634
Seaboard Corp
SEB
$4.08B
| $2.37M | ﹤0.01% |
557
+9
| +2% | +$37.7K |
|
|
RAVN
1635
DELISTED
Raven Industries Inc
RAVN
| $2.37M | ﹤0.01% |
68,700
+1,200
| +2% | +$40.9K |
|
1636
Benchmark Electronics
BHE
$2.89B
| $2.36M | ﹤0.01% |
68,600
| – | – |
|
1637
Enterprise Financial Services Corp
EFSC
$2.4B
| $2.36M | ﹤0.01% |
48,864
+1,000
| +2% | +$44.4K |
|
|
GRP.U
1638
DELISTED
Granite Real Estate Investment Trust
GRP.U
| $2.35M | ﹤0.01% |
46,400
+600
| +1% | +$30.2K |
|
1639
MACOM Technology Solutions
MTSI
$23.5B
| $2.35M | ﹤0.01% |
88,450
+2,400
| +3% | +$57.3K |
|
1640
Central Garden & Pet Co Class A
CENTA
$2.41B
| $2.35M | ﹤0.01% |
99,875
+750
| +0.8% | +$16.8K |
|
1641
DNOW Inc
DNOW
$2.95B
| $2.34M | ﹤0.01% |
208,300
+4,600
| +2% | +$51.3K |
|
|
WDR
1642
DELISTED
Waddell & Reed Financial, Inc.
WDR
| $2.34M | ﹤0.01% |
140,000
-1,000
| -0.7% | -$16.3K |
|
1643
Cardlytics
CDLX
$25.1M
| $2.34M | ﹤0.01% |
+3,720
| New | +$1.82M |
|
1644
CVR Energy
CVI
$3.58B
| $2.33M | ﹤0.01% |
57,700
+1,100
| +2% | +$48.3K |
|
1645
Materion
MTRN
$5.88B
| $2.32M | ﹤0.01% |
39,100
+900
| +2% | +$53.2K |
|
1646
Brookdale Senior Living
BKD
$3B
| $2.32M | ﹤0.01% |
319,539
+5,200
| +2% | +$38.6K |
|
|
SFIX
1647
Stitch Fix
SFIX
$487M
| $2.32M | ﹤0.01% |
90,500
+11,900
| +15% | +$276K |
|
1648
OFG Bancorp
OFG
$2.26B
| $2.32M | ﹤0.01% |
98,200
+1,700
| +2% | +$37.1K |
|
|
DCH
1649
Dauch Corp
DCH
$1.6B
| $2.32M | ﹤0.01% |
215,300
+4,200
| +2% | +$40K |
|
|
RPT
1650
DELISTED
RPT Realty Common Shares of Beneficial Interest (MD)
RPT
| $2.31M | ﹤0.01% |
153,900
+3,200
| +2% | +$45.7K |
|
Similar funds
Swiss National Bank's Q4 2019 Portfolio in Review
As of Q4 2019, Swiss National Bank held 2,602 positions worth $97.5B, up 3.6% from $94.1B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Swiss National Bank withdrew a net $3.98B in Q4 2019, closing 96 positions and reducing 725 holdings. Its most notable exit was Celgene Corp, an estimated $231M position sold in full.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Swiss National Bank opened a new position in Match Group worth $14.7M.
- Swiss National Bank's largest Q4 2019 buy was Match Group: 179,200 shares worth $14.7M.
- Swiss National Bank added most to Bristol-Myers Squibb in Q4 2019, an estimated $114M increase.
- Swiss National Bank's biggest Q4 2019 reduction was Apple, cutting an estimated $249M.
- Swiss National Bank fully exited Celgene Corp in Q4 2019, selling an estimated $231M.
- Swiss National Bank's ten largest holdings make up 19% of its $97.5B portfolio in Q4 2019.
- Swiss National Bank opened 82 new positions and closed 96 in Q4 2019.
- Swiss National Bank's portfolio value rose 3.6% quarter-over-quarter to $97.5B.
Based on Swiss National Bank's 13F filing for Q4 2019, filed 6 Feb 2020.